Established resources for pharmacogenetic guidance were identified, and recommendations were evaluated for UGT1A1-guided therapy for irinotecan, belinostat, pazopanib, or nilotinib to elucidate further the role of UGT1A1 in guiding cancer pharmacotherapy. Here, UGT1A1 is linked to cancer.